- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03774901
Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (PULSE)
Activity and Tolerability of Maintenance Avelumab Immunotherapy After First Line Polychemotherapy Including Platinum in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
Patients with unresectable locally advanced or metastatic squamous cell penile carcinoma (SPC) who are in response or with stable disease after first line platinum containing polychemotherapy who meet the inclusion/exclusion criteria will be offered to take part in the study.
The patients may be pre-screened at the time of the 1st line chemotherapy.
In order for patients to be enrolled, the investigator must have carried out a radiological assessment of the disease during first line systemic treatment (a maximum of between 3 and 6 cycles): the cancer must be controlled. Patients with disease progression cannot be included in the PULSE study as this is a maintenance study.
After inclusion, Avelumab will be administered at a dose of 10 mg/kg, at a frequency of once every 2 weeks with appropriate supportive care.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Elise Robert
- Phone Number: 0033381219086
- Email: e1robert@chu-besancon.fr
Study Contact Backup
- Name: Diane Berthod
- Phone Number: 0033370632403
- Email: dberthod@chu-besancon.fr
Study Locations
-
-
-
Besançon, France, 25000
- Recruiting
- Antoine THIERY VUILLEMIN
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Eligibility Criteria
Inclusion:
- Histologically confirmed unresectable locally advanced or metastatic squamous cell penile carcinoma
- Patients who have received a minimum of 3 and a maximum of 6 cycles of polychemotherapy including a platinum (cisplatin or carboplatin) administered as 1st line systemic treatment.
In the event of pretreatment with cisplatin: a cumulative minimum dose of 210 mg/m2 is required in order to be eligible.
In the event of pretreatment with carboplatin: a minimum cumulative dose equivalent to 3 cycles of carboplatin AUC5 is required to be eligible
- Patients without disease-progression according to the RECIST v1.1 criteria (i.e. in complete or partial response or stable disease at inclusion) after 3 to 6 cycles of 1st line chemotherapy.
- ECOG (Eastern Cooperative Group) performance status of 0 to 2
- Adequate organ function:
Absolute neutrophil (N) count ≥ 1500/mm3 ou ≥ 1,5.10^9/L Platelets ≥ 100 000 / mm3 Haemoglobin ≥ 9 g/dL Creatinine clearance ≥ 30 mL/min (by the MDRD formula) Total bilirubin ≤ 1.5 x ULN (upper limit of the normal range) AST ≤ 2.5 x ULN and ALT ≤ 2.5 x ULN OR AST and ALT ≤ 5 x ULN if liver abnormalities due to liver metastases AST = aspartate aminotransferase ALT = alanine aminotransferase
Exclusion:
- Patients who have never received chemotherapy with a platinum (cisplatin or carboplatin)
- Patients who have received more than one previous line of systemic treatment for penile cancer unless in case of more than 12 months delay between the end of prior treatment and the start of platinum containing polychemotherapy required.
- Patients whose disease has progressed according to RECIST v1.1 criteria after 1st line chemotherapy for penile cancer. The cancer must not be in the progression phase at inclusion
- Past history of immunotherapy treatment with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or an anti- CTLA-4 antibody (including ipilimumab) or any other antibody or medicinal products specifically targeting anti-cancer immunotherapy
- Major surgery within 4 weeks or major radiotherapy within 2 weeks prior to starting avelumab. Previous palliative radiotherapy (≤ 10 fractions) for metastatic lesions is permitted, provided that this has been completed at least 48 hours prior to starting avelumab
- Patients with a past history of known central nervous system metastases, meningeal carcinomatosis or spinal compression
- Existence of a past history of cancer within 3 years prior to inclusion into the study (excluding cured localised cancer such as non-melanomatous skin cancers, superficial bladder cancers and localised prostate cancer with undetectable PSA)
- Active autoimmune disease, which may deteriorate following administration of an immunostimulatory agent. Patients suffering from type I diabetes, vitiligo, psoriasis or hypo- or hyperthyroidism not requiring immunosuppressant treatment are eligible
- Patients with uncontrolled adrenal failure
- Any of the following events in the 3 months prior to inclusion: myocardial infarction, severe/unstable angina, coronary/periphery artery bypass, symptomatic congestive heart failure, cerebrovascular accident, transient ischaemic attack.
- Pulmonary embolism or deep vein thrombosis within 3 months prior to inclusion (unless if stable, asymptomatic and treated with a low molecular heparin for at least 10 days prior to starting the avelumab)
- Active infection requiring systemic treatment
- Current treatment with an immunosuppressant medicinal product or treatment within 7 days prior to inclusion, EXCEPT:
a - Intra-nasal, inhaled or local steroids or local steroid injections (such as intra-articular injections) b - Systemic corticosteroids at physiological doses of ≤ 10 mg/day of prednisone or equivalent c - Steroids as premedication for hypersensitivity reactions (such as CT scan premedication).
- Diagnosis of human immunodeficiency virus (HIV) infection or disease related to the acquired immunodeficiency syndrome (AIDS). In patients who are seropositive for HIV but have a disease deemed to be controlled on anti-viral therapy from the opinion of the patient's HIV contact doctor: inclusion is still possible if the CD4 count is ≥ 300/mm3
- Previous organ transplant including stem cell allotransplantation
- Any screening test for hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating active infection
- Vaccination within 4 weeks prior to first administration of avelumab and throughout the period of the study, except with inactivated vaccines (such as, inactivated influenza vaccines).
- Men of childbearing age who do not wish or cannot use 2 methods of highly effective contraception (oral contraceptives, contraceptive injections, intra-uterine devices, dual barrier method or contraceptive patches) as described in the protocol throughout the study and for at least 60 days after the last dose of avelumab
- Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: avelumab maintenance
Avelumab will be administered at a dose of 10 mg/kg every 2 weeks with appropriate supportive care
|
intravenous 10 mg/kg every 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS (progression-free survival)
Time Frame: 24 months
|
To estimate progression-free survival in patients included in this study
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS (overall survival)
Time Frame: 32 months
|
To estimate overall survival in patients included in this study
|
32 months
|
MDT (median duration of treatment)
Time Frame: 24 months
|
To estimate the median duration of avelumab treatment calculated from avelumab initiation in patients included in this study
|
24 months
|
QOL (quality of life) assessed by EORTC QLQ-C30
Time Frame: 24 months
|
To assess health-related quality of life since avelumab is started in patients included in this study
|
24 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
Time Frame: 24 months
|
To assess safety profile after avelumab initiation
|
24 months
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P/2017/337
- 2018-001427-38 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Penile Cancer
-
The Netherlands Cancer InstituteCompletedHead and Neck Cancer | Penile CancerNetherlands
-
Sun Yat-sen UniversityCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupTerminatedS0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)Penile CancerUnited States
-
Mayo ClinicRecruitingStage IV Penile Cancer AJCC v8 | Stage III Penile Cancer AJCC v8 | Metastatic Penile Squamous Cell Carcinoma | Unresectable Penile Squamous Cell CarcinomaUnited States
-
The Christie NHS Foundation TrustNot yet recruiting
-
European Organisation for Research and Treatment...CompletedPenile CancerFrance, United Kingdom, Poland, Belgium, Netherlands, Hungary
-
Latin American Cooperative Oncology GroupMerck Sharp & Dohme LLCCompleted
-
Queen Mary University of LondonUnknownCharacterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] (MRI-PET)Squamous Cell Carcinoma of the PenisUnited Kingdom
-
Latin American Cooperative Oncology GroupRoche Pharma AGCompletedPenile Squamous Cell CarcinomaBrazil
-
University Health Network, TorontoRecruitingMetastatic Cancer | Advanced Cancer | Penile CancerCanada
Clinical Trials on Avelumab
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Promontory Therapeutics Inc.Pfizer; EMD SeronoCompletedNon-Small Cell Lung Cancer (NSCLC)United States, Switzerland
-
Clinique Neuro-OutaouaisCompletedGlioblastoma Multiforme of BrainCanada
-
4SC AGMerck KGaA, Darmstadt, GermanyWithdrawn
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyActive, not recruitingLymphoma, Extranodal NK-T-CellKorea, Republic of
-
Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsGermany
-
PfizerTerminatedUrinary Bladder Neoplasms | Bladder Cancer | Urothelial Carcinoma | Bladder TumorsCanada
-
Vaccinex Inc.Merck KGaA, Darmstadt, GermanyCompletedCarcinoma, Non-Small-Cell LungUnited States
-
Vaccinex Inc.University of RochesterRecruitingMetastatic Pancreatic AdenocarcinomaUnited States
-
AHS Cancer Control AlbertaEMD Serono; Alberta Cancer FoundationRecruitingSquamous Cell Carcinoma of the SkinCanada